Future pandemics may be fought faster with mRNA and advanced vaccine platforms

The world's experience with COVID-19 reshaped expectations for how quickly vaccines can be developed during a global health emergency. Advances in genetic sequencing, biotechnology, and international collaboration enabled vaccines to be designed and deployed within months. These developments have raised new questions about whether similar technologies could improve preparedness for other major pandemic threats.

In a paper titled "mRNA and Next-Generation Vaccine Platforms for Pandemic Influenza Preparedness," published in Vaccines, researcher Rick A. Bright evaluates how lessons from COVID-19 vaccine development and advances in mRNA technology could help global health systems respond more effectively to future influenza pandemics.

Why pandemic influenza still poses a global threat

Unlike seasonal influenza, which circulates predictably each year, pandemic influenza arises when a novel virus emerges from animal reservoirs and spreads efficiently among humans. These viruses evolve rapidly, often mutating or reassorting their genetic material in ways that make them difficult to predict and control.

Modern global conditions amplify these risks. Rapid international travel enables infectious diseases to spread across continents within days. Human populations are increasingly exposed to animal hosts through agriculture, wildlife trade, and environmental changes. At the same time, influenza viruses remain highly adaptable pathogens capable of rapid genetic shifts.

Despite sustained investments in influenza surveillance and vaccination programs, current vaccine systems remain poorly suited to respond to a pandemic. Most licensed influenza vaccines rely on manufacturing processes that require months of preparation. Producers must select viral strains early in the production cycle, often before scientists fully understand which variants will dominate the outbreak.

This early decision-making introduces a major risk: the vaccine may not match the circulating virus by the time production is completed. If a virus mutates after manufacturing begins, there is little opportunity to adjust vaccine composition. As a result, the protective effect of the vaccine can be reduced.

These structural limitations highlight the need for more adaptable vaccine technologies capable of responding to rapidly evolving pathogens.

How mRNA platforms could transform pandemic response

The study argues that messenger RNA vaccine platforms represent one of the most promising tools for improving pandemic preparedness. Unlike traditional vaccines, which rely on growing viruses in eggs or cell cultures, mRNA vaccines use genetic instructions that teach human cells to produce specific viral proteins. This approach allows scientists to design vaccine candidates quickly using only the genetic sequence of the virus.

The COVID-19 pandemic demonstrated the power of this technology. Once the SARS-CoV-2 genome was identified, researchers were able to design mRNA vaccine candidates within weeks. Large-scale manufacturing and clinical trials followed soon afterward, leading to vaccine deployment in record time.

This experience fundamentally changed expectations for vaccine development timelines. Historically, vaccines could take years to develop and produce. The success of mRNA technology showed that safe and effective vaccines could be developed much faster when supported by strong regulatory frameworks, manufacturing infrastructure, and coordinated global investment.

For influenza preparedness, the advantages of mRNA platforms extend beyond speed. Influenza viruses evolve constantly through processes such as antigenic drift, meaning the viral surface proteins targeted by vaccines can change rapidly. Traditional vaccine production requires fixed strain selection months before the vaccine becomes available.

On the other hand, mRNA platforms allow scientists to update vaccine antigen sequences without redesigning the entire manufacturing process. If new viral data emerges during an outbreak, vaccine formulations could potentially be revised quickly.

This flexibility could significantly reduce the consequences of vaccine mismatch, a common problem in seasonal influenza vaccination campaigns. Severe influenza seasons dominated by rapidly evolving strains illustrate how traditional vaccines sometimes struggle to keep pace with viral evolution.

Recent clinical trials also support the feasibility of mRNA vaccines for influenza. Phase III studies of seasonal influenza mRNA vaccines have demonstrated strong immune responses and favorable safety profiles, particularly among older adults who face the highest risk of severe influenza complications.

These findings suggest that mRNA platforms could play a critical role in pandemic response by enabling faster vaccine development and more adaptable manufacturing systems.

Another global initiative shaping pandemic preparedness is the "100 Days Mission," which aims to develop and deploy vaccines for emerging threats within approximately one hundred days of identifying a new pathogen. Achieving this goal will require technologies capable of rapid design, large-scale production, and flexible adaptation as outbreaks evolve.

Building a diverse and resilient vaccine ecosystem

While mRNA technology offers significant advantages, the study emphasizes that pandemic preparedness should not rely on a single vaccine platform. Traditional influenza vaccines remain a vital component of global health systems and continue to provide large-scale production capacity.

Conventional vaccine approaches include egg-based vaccines, cell-culture vaccines, recombinant protein vaccines, and live attenuated influenza vaccines. These technologies benefit from decades of regulatory experience and established manufacturing infrastructure.

Egg-based vaccines, for example, still account for the majority of global influenza vaccine production. However, these systems depend on large supplies of fertilized eggs and require extended production timelines. During a pandemic, these limitations can delay vaccine availability.

Cell-based and recombinant vaccines offer greater flexibility and avoid some of the constraints associated with egg-based production. However, they still involve manufacturing processes that may not adapt quickly enough during rapidly evolving outbreaks.

Emerging vaccine technologies aim to expand the range of tools available for pandemic response. Nanoparticle-based vaccines are being explored to enhance immune responses by presenting viral proteins in optimized structures. Self-amplifying RNA vaccines represent another promising approach that could reduce the amount of vaccine material required per dose, potentially expanding supply during emergencies.

Researchers are also investigating advanced protein expression systems using microbial, plant-based, or cell-free technologies to accelerate vaccine manufacturing and reduce costs.

The study suggests that combining multiple vaccine technologies could create a more resilient preparedness system. If one platform encounters manufacturing or regulatory obstacles, alternative approaches could still provide protection.

Manufacturing capacity and supply chain resilience remain critical challenges in global pandemic response. Vaccine production relies on complex networks of raw materials, specialized equipment, and skilled personnel. Even highly adaptable platforms require operational facilities capable of scaling production quickly.

To address this issue, global health organizations are promoting the concept of "warm-base" manufacturing. This approach involves maintaining vaccine production infrastructure and trained workforces even during periods without active pandemics. By keeping facilities operational, manufacturers can rapidly expand production when a new threat emerges.

Expanding regional manufacturing capacity is another important priority. Many low- and middle-income countries currently depend on vaccine imports from a small number of manufacturing hubs. During pandemics, these supply chains can become strained, leading to unequal access to life-saving vaccines.

Programs such as the World Health Organization's mRNA technology transfer initiative aim to help countries develop their own vaccine production capabilities. These efforts focus on building technical expertise, regulatory capacity, and supply networks that can support local manufacturing.

Scientific challenges also remain. Influenza viruses interact with the immune system in complex ways that complicate vaccine development. Previous exposure to influenza strains can influence how the immune system responds to new vaccines, a phenomenon known as immune imprinting.

Researchers are also working to identify more reliable indicators of vaccine protection beyond traditional antibody measurements. Advances in immunology and systems biology may help scientists design vaccines that provide broader and longer-lasting protection.

Artificial intelligence and computational biology are emerging as powerful tools in this effort. Machine learning algorithms can analyze large datasets of viral genetic sequences to predict how influenza viruses may evolve. These insights can guide vaccine design and help scientists target viral regions less likely to mutate.

New vaccine delivery technologies may also play a role in improving pandemic response. Microneedle patches, for example, could allow vaccines to be administered without traditional syringes, simplifying mass vaccination campaigns. Oral vaccine formulations and thermostable vaccines that do not require ultra-cold storage could further improve access in resource-limited regions.

Maintaining public trust will be equally important. Rapid vaccine development must be accompanied by transparent safety monitoring and clear communication about benefits and risks. Large-scale safety monitoring systems implemented during the COVID-19 pandemic demonstrated that adverse events can be detected and investigated quickly even during mass vaccination campaigns.